Skip to main content

Table 1 The different thresholds of the number of somatic mutations used to define high and low TMB, the corresponding number of low TMB patients per each threshold (N < Threshold) in the discovery phase, and associations with OS in discovery, validation, and pooled cohorts

From: Tumor immunogenomic signatures improve a prognostic model of melanoma survival

TMB Threshold N < Threshold Discovery (N = 139) Validation 1 (N = 70) Pooled (Discovery + Validation 1) (N = 209)
P HR (95% CI) P HR (95% CI) P HR (95% CI)
50 17 (12.2%) 8.64E−05 4.28 (2.07–8.84)     
75 23 (16.5%) 4.57E−05 3.69 (1.97–6.92)     
100 28 (20.1%) 1.11E−04 3.18 (1.77–5.71)     
125 34 (24.5%) 1.30E−05 3.52 (2.00–6.20) 0.01 2.86 (1.23–6.62) 4.01E−07 3.36 (2.10–5.36)
150 36 (25.9%) 3.36E−05 3.15 (1.83–5.41)     
175 40 (28.8%) 2.24E−04 2.78 (1.62–4.78)     
200 46 (33.1%) 2.22E−03 2.28 (1.34–3.86)     
323 71 (51.1%) 8.69E−02 1.59 (0.94–2.70)     
  1. The p-values (P), hazard ratios and 95% confidence intervals (HR 95% CI) for each threshold in the discovery phase were derived from univariate Cox PH models. The 125-mutation threshold (italic), which had the most significant p-value in the discovery phase, was moved forward to the validation stage. The p-value (P), hazard ratio, and 95% confidence interval (HR 95% CI) from the univariate Cox PH model from the validation phase are also included. The final two columns present the p-value (P) from the meta-analysis of the entire population, with accompanying hazard ratio and 95% confidence interval (HR 95% CI) from a univariate Cox PH model